AR082727A1 - Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen - Google Patents
Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR082727A1 AR082727A1 ARP110103112A AR082727A1 AR 082727 A1 AR082727 A1 AR 082727A1 AR P110103112 A ARP110103112 A AR P110103112A AR 082727 A1 AR082727 A1 AR 082727A1
- Authority
- AR
- Argentina
- Prior art keywords
- denotes
- mono
- nhet3
- conh
- hal
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 3
- -1 phenoxy, benzyloxy Chemical group 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 229910006069 SO3H Inorganic materials 0.000 abstract 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 2
- 235000010290 biphenyl Nutrition 0.000 abstract 2
- 239000004305 biphenyl Substances 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Gynecology & Obstetrics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Transplantation (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Son inhibidores de Syk y se pueden emplear, entre otros, para el tratamiento de artritis reumatoidea y/o lupus sistémico.Reivindicación 1: Compuestos de la fórmula (1) en donde R1 denota Ar1 o Het1; R2 denota Ar2, Het2, NH(CH2)nAr2, O(CH2)nAr2 o NH(CH2)nHet2; Ar1 denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, O(CH2)pCyc, Alk, (CH2)nOH, (CH2)nOA, (CH2)nCOOH, (CH2)nCOOA, S(O)mA, fenoxi, benciloxi, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, [C(R3)2]nCN, NO2, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2NH2, SO2NHA, SO2NA2, NHCONH2, (CH2)nNHCOA, (CH2)nNHCOAlk, NHCOCH=CH(CH2)pNA2, CHO, COA, SO3H, O(CH2)pNH2, O(CH2)pNHCOOA, O(CH2)pNHA, O(CH2)pNA2, NH(CH2)pNH2, NH(CH2)pNHCOOA, NH(CH2)pNHA, NH(CH2)pNA2, NHCOHet3, COHet3, (CH2)nHet3, O(CH2)nHet3 y/u O(CH2)nCH(OH)(CH2); Ar2 denota fenilo, naftilo o bifenilo, cada uno de los cuales no está sustituido o está mono-, di- o trisustituido con Hal, A, (CH2)nOH, (CH2)nOA, O(CH2)pCyc, OAr3, benciloxi, (CH2)nCOOH, (CH2)nCOOA, S(O)mA, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, [C(R3)2]nCN, NO2, CONH(CH2)pNH2, CONH(CH2)pNHA, CONH(CH2)pNA2, CONH(CH2)pOA, CONH(CH2)pOH, (CH2)nCONH2, (CH2)nCONHA, (CH2)nCONA2, SO2NH2, SO2NHA, SO2NA2, NHCONH2, (CH2)nNHCOA, (CH2)nNHCOAlk, CHO, COA, SO3H, O(CH2)pNH2, O(CH2)pNHA, O(CH2)pNA2, CONHAr3, NHCOAr3, CONH(CH2)nHet3, NHCOHet3, COHet3, (CH2)nHet3, S(CH2)nHet3 y/u O(CH2)nHet3; Het1 denota un heterociclo aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono- o disustituido con A, bencilo, Het4, OH y/u OA; Het2 denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di-, tri- o tetrasustituido con Hal, A, (CH2)nHet4, OHet4, NH(CH2)nHet4, (CH2)nCOOH, (CH2)nCOOA, fenilo, bencilo, CHO, COA, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, CN, (CH2)nOH, (CH2)nOA, (CH2)pCH(OH)(CH2)pOH, (CH2)pCH(OH)(CH2)pOA, NH(CH2)pNH2, NHSO2A, NASO2A, SO2A y/u =O; Het3 denota un heterociclo saturado, insaturado o aromático mono- o bicíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di-, tri- o tetrasustituido con A, Hal, (CH2)nNH2, (CH2)nNHA, (CH2)nNA2, (CH2)nOH, (CH2)nOA, COOA, Ar3 y/u =O; Het4 denota un heterociclo saturado, insaturado o aromático monocíclico que tiene 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con A; R3 denota H o alquilo C1-4; A denota alquilo C1-10 no ramificado o ramificado, en donde 1 - 7 átomos de H pueden estar reemplazados por F y/o Cl y/o en donde uno o dos grupos no adyacentes CH2 pueden estar reemplazados por O, NH, S, SO, SO2 y/o por grupos CH=CH, o alquilo cíclico C3-7, que puede no estar sustituido o que puede estar sustituido con OH, NHCOOA o NH2; Cyc denota alquilo cíclico C3-7; Alk denota alquenilo o alquinilo C2-6; Ar3 denota fenilo, que no está sustituido o está mono-, di- o trisustituido con Hal y/o A; Hal denota F, Cl, Br o I; m denota 0, 1 ó 2; n denota 0, 1, 2, 3 ó 4; p denota 1, 2, 3 ó 4; y sus solvatos, sales, tautómeros y estereoisómeros farmacéuticamente aceptables, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10008928 | 2010-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR082727A1 true AR082727A1 (es) | 2012-12-26 |
Family
ID=44501791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110103112 AR082727A1 (es) | 2010-08-27 | 2011-08-26 | Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen |
Country Status (15)
Country | Link |
---|---|
US (1) | US9006440B2 (es) |
EP (1) | EP2609100B1 (es) |
JP (1) | JP5789300B2 (es) |
KR (1) | KR20130108318A (es) |
CN (1) | CN103052640B (es) |
AR (1) | AR082727A1 (es) |
AU (1) | AU2011295441B2 (es) |
BR (1) | BR112013004624A2 (es) |
CA (1) | CA2809333C (es) |
EA (1) | EA201300283A1 (es) |
ES (1) | ES2545352T3 (es) |
IL (1) | IL224870A (es) |
MX (1) | MX2013002199A (es) |
SG (1) | SG187956A1 (es) |
WO (1) | WO2012025187A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013014708B1 (pt) | 2011-02-28 | 2021-10-19 | Sunshine Lake Pharma Co., Ltd. | Composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
BR112014017762A8 (pt) * | 2012-02-09 | 2017-07-11 | Merck Patent Gmbh | Derivados de furo[3,2-b]- e tieno[3,2-b]piridina como inibidores de tbk1 e ikk, seus usos, processo para a preparação dos mesmos e medicamentos que os compreendem |
WO2013124025A1 (en) * | 2012-02-21 | 2013-08-29 | Merck Patent Gmbh | Furopyridine derivatives |
US8975282B2 (en) | 2012-07-28 | 2015-03-10 | Sunshine Lake Pharma Co., Ltd. | Substituted pyrazolone compounds and methods of use |
WO2014022117A1 (en) | 2012-07-28 | 2014-02-06 | Calitor Sciences, Llc | Substituted pyrazolone compounds and methods of use |
CZ2014295A3 (cs) * | 2014-04-30 | 2015-10-14 | Masarykova Univerzita | Substituované furo[3,2-b]pyridiny pro použití jako léčiva |
CA2985859A1 (en) * | 2015-06-29 | 2017-01-05 | Merck Patent Gmbh | Tbk/ikk.epsilon. inhibitor compounds and uses thereof |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2024033281A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furo pyrimidine derivates |
WO2024033280A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040142A1 (en) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | Heterocyclic ring-fused pyrimidine derivatives |
US6187777B1 (en) * | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US20020004511A1 (en) | 2000-06-28 | 2002-01-10 | Luzzio Michael Joseph | Thiophene derivatives useful as anticancer agents |
US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
NZ589336A (en) * | 2008-03-05 | 2011-12-22 | Methylgene Inc | Pyridine derivatives as inhibitors of protein tyrosine kinase activity |
WO2009136995A2 (en) | 2008-04-16 | 2009-11-12 | Portola Pharmaceuticals, Inc. | Inhibitors of syk protein kinase |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
-
2011
- 2011-07-29 MX MX2013002199A patent/MX2013002199A/es not_active Application Discontinuation
- 2011-07-29 ES ES11738631T patent/ES2545352T3/es active Active
- 2011-07-29 WO PCT/EP2011/003831 patent/WO2012025187A2/en active Application Filing
- 2011-07-29 BR BR112013004624A patent/BR112013004624A2/pt not_active IP Right Cessation
- 2011-07-29 KR KR20137007836A patent/KR20130108318A/ko not_active Application Discontinuation
- 2011-07-29 SG SG2013013990A patent/SG187956A1/en unknown
- 2011-07-29 CA CA2809333A patent/CA2809333C/en not_active Expired - Fee Related
- 2011-07-29 JP JP2013525161A patent/JP5789300B2/ja not_active Expired - Fee Related
- 2011-07-29 EP EP11738631.8A patent/EP2609100B1/en not_active Not-in-force
- 2011-07-29 AU AU2011295441A patent/AU2011295441B2/en not_active Ceased
- 2011-07-29 EA EA201300283A patent/EA201300283A1/ru unknown
- 2011-07-29 US US13/819,166 patent/US9006440B2/en not_active Expired - Fee Related
- 2011-07-29 CN CN201180041050.9A patent/CN103052640B/zh not_active Expired - Fee Related
- 2011-08-26 AR ARP110103112 patent/AR082727A1/es unknown
-
2013
- 2013-02-21 IL IL224870A patent/IL224870A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ES2545352T3 (es) | 2015-09-10 |
JP5789300B2 (ja) | 2015-10-07 |
US20130225569A1 (en) | 2013-08-29 |
SG187956A1 (en) | 2013-03-28 |
MX2013002199A (es) | 2013-03-18 |
EP2609100A2 (en) | 2013-07-03 |
EA201300283A1 (ru) | 2013-08-30 |
WO2012025187A2 (en) | 2012-03-01 |
KR20130108318A (ko) | 2013-10-02 |
IL224870A (en) | 2016-05-31 |
BR112013004624A2 (pt) | 2016-07-05 |
US9006440B2 (en) | 2015-04-14 |
EP2609100B1 (en) | 2015-06-24 |
CN103052640A (zh) | 2013-04-17 |
JP2013536208A (ja) | 2013-09-19 |
WO2012025187A3 (en) | 2012-06-21 |
AU2011295441A1 (en) | 2013-04-11 |
CA2809333C (en) | 2018-09-25 |
AU2011295441B2 (en) | 2015-04-09 |
CA2809333A1 (en) | 2012-03-01 |
CN103052640B (zh) | 2017-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR082727A1 (es) | Derivados de furopiridina, procesos de preparacion y composiciones farmaceuticas que los contienen | |
AR082726A1 (es) | Derivados de triazolopirazina | |
AR082722A1 (es) | Derivados de pirimidina | |
AR078313A1 (es) | Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras | |
AR096235A1 (es) | Arilquinazolinas | |
AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
AR057214A1 (es) | Derivados de piridazinona como inhibidores, reguladores o moduladores de quinasas. | |
ES2587953T3 (es) | Amidas cíclicas como inhibidores de MetAP-2 | |
AR092365A1 (es) | Derivados de piridopirimidina | |
AR067506A1 (es) | Derivados de quinazolinamida | |
AR082728A1 (es) | Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos | |
AR055376A1 (es) | Derivados de 1-acildihidropirazol | |
AR083402A1 (es) | Pirrolidinonas como inhibidores de metap-2 | |
AR066543A1 (es) | Derivados de piridazinona | |
AR068658A1 (es) | Derivados de tiazol | |
AR051795A1 (es) | Derivados de hidantoina inhibidores de metaloproteinasas | |
AR084507A1 (es) | Derivados de indazoliltriazol | |
AR082109A1 (es) | Derivados de bipiridilo | |
AR082414A1 (es) | Carboxamidas azaheterociclicas biciclicas utiles para tratar enfermedades hiperproliferativas e inflamatorias, composiciones farmaceuticas que las contienen y procedimiento para prepararlas | |
AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
EA201591000A1 (ru) | Пирролобензодиазепины | |
AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
AR068659A1 (es) | Derivados de imidazol inhibidores de autotaxina | |
AR072192A1 (es) | Derivados de tiazolil-piperidina | |
AR093725A1 (es) | Quinazolincarboxamida azetidinas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |